<DOC>
	<DOCNO>NCT02063854</DOCNO>
	<brief_summary>The present phase II/III , multicenter , randomize , double-blind , parallel group comparative study design evaluate efficacy safety once-monthly oral administration NE-58095 delay release ( DR ) tablets 12 month participant involutional osteoporosis . For study , participant receive oral NE-58095 immediate release ( IR ) 2.5 mg tablet daily 12 month set control group .</brief_summary>
	<brief_title>A Phase II/III , Double-blind , Parallel Group Comparative Study Oral Administration NE-58095 Tablets</brief_title>
	<detailed_description>The primary objective present study verify non-inferiority once-monthly oral administration NE-58095 DR tablets 12 month once-daily oral administration NE-58095 IR 2.5 mg tablet 12 month , term efficacy participant involutional osteoporosis . Secondary objective present study follow : compare safety once-monthly oral administration NE-58095 DR tablets 12 month safety once-daily oral administration NE-58095 IR tablet ( 2.5 mg ) 12 month participant involutional osteoporosis time wakening .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>1 . Patients diagnosis involutional osteoporosis 2 . Male female outpatient ( include patient admitted hospital test ) age ≥ 50 year time consent 3 . Women least 2 year pass since last natural menstruation 1 . Patients secondary osteoporosis 2 . Patients disease ( secondary osteoporosis ) present decrease bone mass 3 . Patients findings affect measurement mean bone mineral density lumbar spine dualenergy Xray absorptiometry ( DXA ) 4 . Patients history radiotherapy lumbar spine pelvis 5 . Patients plan receive surgical dental procedure tooth extraction ( include dental implant treatment ) treatment period 6 . Patients history treatment antireceptor activator nuclear factorκB ligand ( RANKL ) monoclonal antibody parathyroid hormone product within 1 year start treatment period 7 . Patients history treatment bisphosphonate product within 24 week start treatment period 8 . Patients receive drug affect bone metabolism within 8 week start treatment period 9 . Patients disorder esophagitis , peptic ulcer ( e.g. , esophageal ulcer , gastric ulcer , duodenal ulcer ) , gastrointestinal bleeding 10 . Patients disorder delay esophageal emptying ( e.g. , dysphagia , esophagostenosis , achalasia esophagus ) 11 . Patients hypocalcemia 12 . Patients hypercalcemia 13 . Patients diagnosis renal calculus 14 . Patients serious renal , hepatic , cardiac disease 15 . Patients receive surgical dental procedure , tooth extraction ( include dental implant treatment ) , whose dental problem remain unresolved start treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>